Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2019
2019
Historique:
received:
04
09
2019
accepted:
03
12
2019
entrez:
14
1
2020
pubmed:
14
1
2020
medline:
14
1
2020
Statut:
epublish
Résumé
Malignant pleural mesothelioma (MPM) is a rare, predominantly asbestos-related and biologically highly aggressive tumor associated with a dismal prognosis. Multimodal therapy consisting of platinum-based chemotherapy is the treatment of choice. The reasons underlying the rather poor efficacy of platinum compounds remain largely unknown. Kinase activity might influence cellular response to these regimens. For this exploratory study, we screened MPM cell lines (NCI-H2452, NCI-H2052, and MSTO-211H) differing in response to cisplatin and benign control fibroblasts (MRC-5) for overall phosphorylation patterns as well as kinase activity with respect to cellular response to cisplatin-based therapeutics. We analysed the cell lines for cellular kinases in a high-throughput manner using the highly innovative technique PamGene. Cell state analysis including apoptosis, necrosis, and cell viability was performed by using enzyme activity and fluorescent-based assays. Cisplatin alters cellular phosphorylation patterns affecting cell cycle, migration, adhesion, signal transduction, immune modulation, and apoptosis. In cisplatin-responsive cell lines, phosphorylation of AKT1 and GSK3B was decreased but could not be influenced in cisplatin-resistant NCI-H2452 cells. Cisplatin-responsive cell lines showed increased phosphorylation levels of JNK1/2/3 but decreased phosphorylation in cisplatin-resistant NCI-H2452 cells. Kinase phosphorylation and activity might play a crucial role in cellular response to cytostatic agents. Cisplatin influences phosphorylation patterns with distinct features in cisplatin-resistant cells. These alterations exert a significant impact on cell cycle, migration, adhesion, signal transduction, immune modulation, and apoptosis of the respective tumor cells. Based on our results, the induction of p38 or JNK1/3, or inhibition of AKT1 by, for example, BIA-6, might offer a positive synergistic effect by induction of an apoptotic response to cisplatin-based treatment, thus potentially enhancing the clinical outcome of MPM patients.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant pleural mesothelioma (MPM) is a rare, predominantly asbestos-related and biologically highly aggressive tumor associated with a dismal prognosis. Multimodal therapy consisting of platinum-based chemotherapy is the treatment of choice. The reasons underlying the rather poor efficacy of platinum compounds remain largely unknown. Kinase activity might influence cellular response to these regimens.
MATERIALS AND METHODS
METHODS
For this exploratory study, we screened MPM cell lines (NCI-H2452, NCI-H2052, and MSTO-211H) differing in response to cisplatin and benign control fibroblasts (MRC-5) for overall phosphorylation patterns as well as kinase activity with respect to cellular response to cisplatin-based therapeutics. We analysed the cell lines for cellular kinases in a high-throughput manner using the highly innovative technique PamGene. Cell state analysis including apoptosis, necrosis, and cell viability was performed by using enzyme activity and fluorescent-based assays.
RESULTS
RESULTS
Cisplatin alters cellular phosphorylation patterns affecting cell cycle, migration, adhesion, signal transduction, immune modulation, and apoptosis. In cisplatin-responsive cell lines, phosphorylation of AKT1 and GSK3B was decreased but could not be influenced in cisplatin-resistant NCI-H2452 cells. Cisplatin-responsive cell lines showed increased phosphorylation levels of JNK1/2/3 but decreased phosphorylation in cisplatin-resistant NCI-H2452 cells.
CONCLUSION
CONCLUSIONS
Kinase phosphorylation and activity might play a crucial role in cellular response to cytostatic agents. Cisplatin influences phosphorylation patterns with distinct features in cisplatin-resistant cells. These alterations exert a significant impact on cell cycle, migration, adhesion, signal transduction, immune modulation, and apoptosis of the respective tumor cells. Based on our results, the induction of p38 or JNK1/3, or inhibition of AKT1 by, for example, BIA-6, might offer a positive synergistic effect by induction of an apoptotic response to cisplatin-based treatment, thus potentially enhancing the clinical outcome of MPM patients.
Identifiants
pubmed: 31929796
doi: 10.1155/2019/2902985
pmc: PMC6942867
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2902985Informations de copyright
Copyright © 2019 Sabrina Borchert et al.
Déclaration de conflit d'intérêts
All authors state that they have no conflicts of interest to declare.
Références
Exp Cell Res. 2000 Apr 10;256(1):34-41
pubmed: 10739649
Lung Cancer. 2004 Aug;45 Suppl 1:S103-19
pubmed: 15261443
Thorax. 2003 Mar;58(3):198-203
pubmed: 12612292
Clin Lung Cancer. 2009 Mar;10(2):112-7
pubmed: 19362954
Curr Opin Pulm Med. 2007 Jul;13(4):284-9
pubmed: 17534174
Cancer Res Treat. 2015 Oct;47(4):913-20
pubmed: 25687876
Breast Cancer Res. 2001;3(6):385-9
pubmed: 11737890
Cancer. 2007 Apr 15;109(8):1454-61
pubmed: 17348013
Mol Med Rep. 2017 Dec;16(6):9095-9101
pubmed: 29039558
Clin Cancer Res. 2011 Apr 15;17(8):2581-90
pubmed: 21262916
Clin Cancer Res. 2005 Feb 1;11(3):982-92
pubmed: 15709163
Clin Cancer Res. 2011 Sep 1;17(17):5562-72
pubmed: 21750204
Cancer Res. 2009 Sep 1;69(17):6831-8
pubmed: 19723666
Br J Cancer. 2013 Aug 6;109(3):552-8
pubmed: 23860535
Br J Cancer. 2008 Jul 8;99(1):51-6
pubmed: 18542071
J Thorac Oncol. 2007 Oct;2(10):902-6
pubmed: 17909351
J Clin Oncol. 2006 Mar 20;24(9):1443-8
pubmed: 16549838
Ann Hematol. 1994;69 Suppl 1:S1-6
pubmed: 8061107
Chest. 1998 Mar;113(3):723-31
pubmed: 9515850
Cancer Control. 2003 Jul-Aug;10(4):297-305
pubmed: 12915808
Chest. 2003 Feb;123(2):551-61
pubmed: 12576380
PLoS One. 2011;6(10):e25164
pubmed: 22022380
Nucleic Acids Res. 2012 Nov;40(21):10780-94
pubmed: 22977173
Ther Clin Risk Manag. 2008 Feb;4(1):205-11
pubmed: 18728709
Occup Environ Med. 2004 May;61(5):438-41
pubmed: 15090665
N Engl J Med. 2007 Jul 5;357(1):39-51
pubmed: 17611206
Int J Oncol. 2004 Apr;24(4):1017-26
pubmed: 15010843
Phytomedicine. 2019 May;58:152805
pubmed: 31022663
J Clin Invest. 2010 Jan;120(1):157-67
pubmed: 20038811
Lung Cancer. 2011 Sep;73(3):256-63
pubmed: 21620512
Breast Cancer Res Treat. 2019 Jul;176(2):291-301
pubmed: 31006103
Pharmacol Ther. 1991 Dec;52(3):385-406
pubmed: 1820582
Histopathology. 2012 Mar;60(4):531-46
pubmed: 21916947
Cancer Res. 2008 Jun 15;68(12):4588-96
pubmed: 18559503
J Thorac Oncol. 2012 Jan;7(1):249-56
pubmed: 22031231
Lung Cancer. 2008 Mar;59(3):377-84
pubmed: 17905465
Neoplasia. 2016 Sep;18(9):525-35
pubmed: 27659012
Clin Cancer Res. 2010 Feb 15;16(4):1206-15
pubmed: 20145178
BMC Cancer. 2015 Jul 09;15:510
pubmed: 26156324